Cargando…

Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction

The farnesoid X receptor (FXR) regulates bile acid, lipid and glucose metabolism. Here we show that treatment of mice with glycine-β-muricholic acid (Gly-MCA) inhibits FXR signalling exclusively in intestine, and improves metabolic parameters in mouse models of obesity. Gly-MCA is a selective high-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Changtao, Xie, Cen, Lv, Ying, Li, Jing, Krausz, Kristopher W., Shi, Jingmin, Brocker, Chad N., Desai, Dhimant, Amin, Shantu G., Bisson, William H., Liu, Yulan, Gavrilova, Oksana, Patterson, Andrew D., Gonzalez, Frank J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4682112/ https://www.ncbi.nlm.nih.gov/pubmed/26670557 http://dx.doi.org/10.1038/ncomms10166

Ejemplares similares

Glycine‐β‐muricholic acid antagonizes the intestinal farnesoid X receptor–ceramide axis and ameliorates NASH in mice
por: Jiang, Jie, et al.
Publicado: (2022)

Inhibition of farnesoid X receptor signaling shows beneficial effects in human obesity
por: Gonzalez, Frank J., et al.
Publicado: (2015)

Role of Farnesoid X Receptor and Bile Acids in Hepatic Tumor Development
por: Takahashi, Shogo, et al.
Publicado: (2018)

Farnesoid X Receptor Signaling Shapes the Gut Microbiota and Controls Hepatic Lipid Metabolism
por: Zhang, Limin, et al.
Publicado: (2016)

Impaired Intestinal Farnesoid X Receptor Signaling in Cystic Fibrosis Mice
por: Ikpa, Pauline T., et al.
Publicado: (2019)

Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats
por: Ceulemans, Laurens J., et al.
Publicado: (2017)

Metabolic adaptation to intermittent fasting is independent of peroxisome proliferator-activated receptor alpha
por: Li, Guolin, et al.
Publicado: (2017)

Notch Activation Is Dispensable for D, L-Sulforaphane-Mediated Inhibition of Human Prostate Cancer Cell Migration
por: Hahm, Eun-Ryeong, et al.
Publicado: (2012)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Enhanced Alcoholic Liver Disease in Mice with Intestine-specific Farnesoid X Receptor Deficiency
por: Huang, Mingxing, et al.
Publicado: (2020)

The Essential Role of Selenoproteins in the Resolution of Citrobacter rodentium-Induced Intestinal Inflammation
por: Nettleford, Shaneice K., et al.
Publicado: (2020)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Inhibition of Retrograde Transport Limits Polyomavirus Infection In Vivo
por: Maru, Saumya, et al.
Publicado: (2017)

Intestinal Farnesoid X Receptor Activation by Pharmacologic Inhibition of the Organic Solute Transporter α-β
por: van de Wiel, Sandra M.W., et al.
Publicado: (2017)

Fibroblast Growth Factor 19 modulates intestinal microbiota and inflammation in presence of Farnesoid X Receptor
por: Gadaleta, Raffaella Maria, et al.
Publicado: (2020)

A novel role for farnesoid X receptor in the bile acid‐mediated intestinal glucose homeostasis
por: Zhao, Long, et al.
Publicado: (2020)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells
por: Li, Jingxia, et al.
Publicado: (2004)

PI-3K and Akt are mediators of AP-1 induction by 5-MCDE in mouse epidermal Cl41 cells
por: Li, Jingxia, et al.
Publicado: (2009)

Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor
por: Tveter, Kevin M, et al.
Publicado: (2020)

Intestinal Farnesoid X Receptor Modulates Duodenal Surface Area but Does Not Control Glucose Absorption in Mice
por: Yang, Jiufang, et al.
Publicado: (2023)

Xanthohumol ameliorates Diet-Induced Liver Dysfunction via Farnesoid X Receptor-Dependent and Independent Signaling
por: Paraiso, Ines L., et al.
Publicado: (2021)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Duodenal-jejunal bypass reduces serum ceramides via inhibiting intestinal bile acid-farnesoid X receptor pathway
por: Cheng, Zhi-Qiang, et al.
Publicado: (2022)

Ginsenoside Rc attenuates DSS-induced ulcerative colitis, intestinal inflammatory, and barrier function by activating the farnesoid X receptor
por: Tang, Kaijia, et al.
Publicado: (2022)

Efficient Synthesis for Altering Side Chain Length on Cannabinoid Molecules and Their Effects in Chemotherapy and Chemotherapeutic Induced Neuropathic Pain
por: Raup-Konsavage, Wesley M., et al.
Publicado: (2022)

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Role of farnesoid X receptor and bile acids in alcoholic liver disease
por: Manley, Sharon, et al.
Publicado: (2015)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_772mmc9teamq6497n2s3mb92ck